Aarti Drugs Limited announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, following its Board of Directors meeting held on May 15, 2026. On a consolidated basis, the company reported a total income of ₹72,106 lakhs for the current quarter, registering a substantial growth compared to the previous quarter’s total income of ₹60,294 lakhs, though experiencing a marginal increase from ₹67,863 lakhs in the corresponding quarter of the previous year. The consolidated net profit for the quarter stood at ₹5,526 lakhs, reflecting an impressive sequential increase from ₹4,055 lakhs in the quarter ended December 31, 2025, but showing a moderate decrease from ₹6,277 lakhs reported during the same period last year. On a quarter-on-quarter (QoQ) basis, consolidated revenue from operations surged by ₹11,859 lakhs or 19.71%, while net profit grew by ₹1,471 lakhs or 36.28%. Year-on-year (YoY), consolidated revenue from operations increased by ₹4,354 lakhs or 6.43%, while consolidated net profit witnessed a decline of ₹751 lakhs or 11.96%. Standalone revenue from operations grew to ₹63,168 lakhs from ₹52,880 lakhs QoQ and ₹62,296 lakhs YoY. Standalone net profit stood at ₹4,496 lakhs, increasing sequentially from ₹3,384 lakhs, but lower than the ₹6,148 lakhs from the corresponding quarter of the previous year.

Aarti Drugs Limited, established in 1984, operates as a prominent pharmaceutical company primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), pharma intermediates, and specialty chemicals. The company operates a single business segment, pharmaceuticals, through multiple manufacturing facilities and possesses several domestic and international subsidiaries, including Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited. Beside the financial reviews, the company re-appointed M/s GMVP & Associates LLP, Cost Accountant, as its Cost Auditor for the financial year ending March 31, 2027, and M/s Raman S. Shah & Co., Chartered Accountant, as its Internal Auditor for three consecutive financial years starting April 1, 2026. The board also reconstituted its Risk Management Committee to incorporate Shri Narendra J. Salvi as a member with immediate effect.